SG Americas Securities
KALV

SG Americas Securities’s KalVista Pharmaceuticals KALV Stock Holding History

SG Americas Securities’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Sell
21,828
-26,202
-55% -$422K ﹤0.01% 2249
2025
Q4 		$776K Buy
48,030
+6,410
+15% +$84.9K ﹤0.01% 2211
2025
Q3 		$507K Buy
+41,620
New +$575K ﹤0.01% 2102
2025
Q1 		– Sell
-14,508
Closed -$123K – 3607
2024
Q4 		$123K Buy
14,508
+1,319
+10% +$13.7K ﹤0.01% 2579
2024
Q3 		$153K Buy
+13,189
New +$166K ﹤0.01% 2715
2024
Q2 		– Sell
-12,082
Closed -$143K – 3074
2024
Q1 		$143K Sell
12,082
-125,735
-91% -$1.68M ﹤0.01% 2245
2023
Q4 		$1.69M Buy
137,817
+6,670
+5% +$60.7K 0.02% 756
2023
Q3 		$1.26M Buy
131,147
+9,794
+8% +$100K 0.01% 1079
2023
Q2 		$1.09M Buy
+121,353
New +$1.12M 0.01% 1012
2023
Q1 		– Sell
-15,734
Closed -$106K – 3415
2022
Q4 		$106K Sell
15,734
-823
-5% -$4.41K ﹤0.01% 2680
2022
Q3 		$240K Sell
16,557
-134
-0.8% -$1.87K ﹤0.01% 2164
2022
Q2 		$164K Buy
+16,691
New +$184K ﹤0.01% 2805
2022
Q1 		– Sell
-11,956
Closed -$158K – 3214
2021
Q4 		$158K Sell
11,956
-6,042
-34% -$96.2K ﹤0.01% 2791
2021
Q3 		$314K Sell
17,998
-5,092
-22% -$103K ﹤0.01% 2905
2021
Q2 		$553K Buy
23,090
+678
+3% +$17.7K ﹤0.01% 1891
2021
Q1 		$576K Buy
22,412
+16,936
+309% +$445K ﹤0.01% 1924
2020
Q4 		$104K Buy
+5,476
New +$93.9K ﹤0.01% 3019
2016
Q1 		– Sell
-871
Closed -$44K – 3105
2015
Q4 		$44K Sell
871
-453
-34% -$23.7K ﹤0.01% 2485
2015
Q3 		$66K Buy
+1,324
New +$113K ﹤0.01% 1938

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG Americas Securities's KALV Position: Q1 2026 in Review

SG Americas Securities reduced its KalVista Pharmaceuticals (KALV) stake by 55% in Q1 2026, selling an estimated $422K and leaving 21,828 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

SG Americas Securities first reported a position in KALV in Q3 2015 and has held it in 19 quarters since. The position peaked at $1.69M in Q4 2023. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • SG Americas Securities held 21,828 shares of KalVista Pharmaceuticals worth $439K as of Q1 2026.
  • SG Americas Securities sold 26,202 KalVista Pharmaceuticals shares in Q1 2026, an estimated $422K.
  • KalVista Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2249 holding.
  • SG Americas Securities first reported a position in KalVista Pharmaceuticals in Q3 2015 and has held it in 19 quarters since.
  • SG Americas Securities's KalVista Pharmaceuticals position peaked at $1.69M in Q4 2023.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.